Suramin sodium salt Clinical Trials

Size	Price	Qty
5mg	USD 190
25mg	USD 370

Clinical Trials

Suramin sodium salt has been evaluated across multiple clinical trials spanning Phase I through Phase III for autism spectrum disorder and several oncological indications, including non-small cell lung, prostate, bladder, and breast cancers. Sponsored by organizations such as the National Cancer Institute, Cancer Research UK, the Eastern Cooperative Oncology Group, and Paxmedica, these studies assessed suramin as a monotherapy or in combination with docetaxel. Although recruitment records indicate that these trials are predominantly completed or terminated, they collectively illustrate significant clinical interest across diverse disease contexts.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06866275	RECRUITING	Autism Spectrum Disorder (ASD)	Children's Hospital of Orange County	2025-04-09	PHASE2
NCT04496596	UNKNOWN	Acute Kidney Injury	Rediscovery Life Sciences	2020-11-13	PHASE2
NCT06058962	COMPLETED	Autism Spectrum Disorder	Paxmedica	2019-06-01	PHASE2
NCT03804749	UNKNOWN	Hand, Foot and Mouth Disease	First Affiliated Hospital of Zhejiang University	2018-12-19	PHASE1
NCT02508259	COMPLETED	Autism Spectrum Disorders	University of California, San Diego	2015-05	PHASE1; PHASE2
NCT01671332	COMPLETED	Carcinoma, Non Small Cell Lung	University of Wisconsin, Madison	2012-06	PHASE2
NCT01038752	TERMINATED	Non-small Cell Lung Cancer	Optimum Therapeutics, LLC	2010-08	PHASE2
NCT00054028	COMPLETED	Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer	National Cancer Institute (NCI)	2002-12	PHASE1; PHASE2
NCT00066768	COMPLETED	Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer	National Cancer Institute (NCI)	2003-07	PHASE1
NCT00006929	COMPLETED	Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer	National Cancer Institute (NCI)	2000-09	PHASE2
NCT00083109	COMPLETED	Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer	National Cancer Institute (NCI)	2004-03	PHASE1; PHASE2
NCT00002921	TERMINATED	Adrenocortical Carcinoma	SWOG Cancer Research Network	1997-03	PHASE2
NCT00004073	COMPLETED	Brain and Central Nervous System Tumors	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	1999-12	PHASE2
NCT00003038	COMPLETED	Adrenocortical Carcinoma; Breast Cancer; Colorectal Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific	Mayo Clinic	1997-10	PHASE1
NCT00002723	COMPLETED	Prostate Cancer	National Cancer Institute (NCI)	1996-01	PHASE3
NCT00002881	COMPLETED	Prostate Cancer	Eastern Cooperative Oncology Group	1996-10	PHASE3
NCT00006476	COMPLETED	Bladder Cancer	Cancer Research UK	2000-10	PHASE1
NCT00001381	COMPLETED	Bladder Neoplasms; Carcinoma, Transitional Cell	National Cancer Institute (NCI)	1994-03	PHASE1
NCT00002652	COMPLETED	Multiple Myeloma and Plasma Cell Neoplasm	University of Arkansas	1995-05	PHASE2
NCT00001266	COMPLETED	Prostatic Neoplasm	National Cancer Institute (NCI)	1990-10	PHASE2
NCT00002639	COMPLETED	Brain and Central Nervous System Tumors	Emory University	1995-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-30)

Check the Suramin sodium salt product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Suramin sodium salt acts as a reversible, competitive inhibitor of protein-tyrosine phosphatases, sirtuins, and topoisomerase II, thereby disrupting intracellular phosphorylation cascades, epigenetic modifications, and DNA replication processes required for cellular proliferation. This multi-target biochemical inhibition suppresses cell survival signaling and arrests cell cycle progression, providing the biological basis for its evaluation in clinical trials targeting advanced malignancies such as prostate, bladder, and non-small cell lung cancers.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).